降压药依普利酮的说明书

Hypertension is a disease that everyone is familiar with. Hypertension is currently the most common chronic disease among Chinese people. Severe hypertension may lead to serious complications such as cerebral infarction and cerebral hemorrhage, and even threaten people's lives. It was first approved for marketing in the United States in 2002. It has definite effects on the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Patients must read the instructions carefully before starting treatment with a new medicine.

Generic name: eplerenone

Product name:Planep

Full names: eplerenone, Inspra, eplerenone, Planep

Indications: For the treatment of congestive heart failure after acute myocardial infarction and the treatment of hypertension in adult patients.

Mechanism of Action: Eplerenone binds to the mineralocorticoid receptor, thereby blocking the binding of aldosterone, a component of the renin-angiotensin-aldosterone system (RAAS). Aldosterone synthesis occurs primarily in the adrenal gland and is regulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in epithelial tissues (such as the kidneys) and non-epithelial tissues (such as the heart, blood vessels, and brain) and increases blood pressure by inducing sodium reabsorption and possibly other mechanisms.

Usage and Dosage: Treatment of congestive heart failure: Adult patients: Initial dose: 25 mg, orally, once a day; and within 4 weeks, gradually increase to the target dose (50 mg, orally, once a day) as tolerated by the patient.

   Treatment of adults with hypertension: Eplerenone can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg, oral, once daily; Maintenance dose: 50 mg, oral, 1-2 times daily; Maximum dose: 100 mg/day.

The above is the instructions for antihypertensive drugs. I hope it will be helpful to you.

Recommended related hot articles: /newsDetail/79968.html